Uricosuric effect of fenofibrate in healthy volunteers

J Clin Pharmacol. 1980 Oct;20(10):560-4. doi: 10.1002/j.1552-4604.1980.tb01670.x.


The uricosuric properties of a single oral dose (300 mg) of fenofibrate, or isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl] propionate (LF 178), a new hypolipidemic drug, have been investigated versus placebo, benzbromarone, with and without urine alkalinization, in ten normouricemic male volunteers, following a crossover design. Twofold increased uric acid clearance values were obtained after fenofibrate and fourfold increased values after benzbromarone. The ratio urinary uric acid/urinary creatinine (UUA/UCr) was enhanced after fenofibrate and benzbromarone versus placebo. The urine alkalinization with fenofibrate intake did increase this ratio to a higher extent.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Benzbromarone / pharmacology
  • Fenofibrate / pharmacology*
  • Humans
  • Male
  • Propionates / pharmacology*
  • Uricosuric Agents*


  • Propionates
  • Uricosuric Agents
  • Benzbromarone
  • Fenofibrate